Table 10.
Non peptide Oxytocin Antagonists and a Nonpeptide Agonist.
| Compound | Number | Code (name) | Company | Supplier | Status | Reference: original synthesis, structure and pharmacologocal properties) | Reference: use |
|---|---|---|---|---|---|---|---|
| OT antagonist | 1 | L-368,899 | Merck | Tocris | Phase II Discontinued | 46, 130 | 134–136 |
| 2 | L-371,257 | Merck | Tocris | Phase II Discontinued | 46 | 141 | |
| 3 | WAY-162720 | Wyeth-Ayerst (now Pfizer) | No | Failed in preclinical | 131 | 141 | |
| 4 | GSK2211149A (Retosiban) | Glaxo SmithKline | Simagchem; Manus Aktteva Biopharma LLP | Phase II completed | 132, 133 | ||
| OT agonist | 1 | WAY-267464 | Wyeth-Ayerst (now Pfizer) | Tocris | Failed in preclinical | 138, 140 | 137, 141 |